205 related articles for article (PubMed ID: 28216139)
1. Investigation of BRAF mutation analysis with different technical platforms in metastatic melanoma.
Sener E; Yildirim P; Tan A; Gokoz O; Tezel GG
Pathol Res Pract; 2017 May; 213(5):522-530. PubMed ID: 28216139
[TBL] [Abstract][Full Text] [Related]
2. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
4. Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma.
Pisareva E; Gutkina N; Kovalenko S; Kuehnapfel S; Hartmann A; Heinzerling L; Schneider-Stock R; Lyubchenko L; Shamanin VA
Melanoma Res; 2014 Aug; 24(4):322-31. PubMed ID: 24922189
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.
Bruno W; Martinuzzi C; Andreotti V; Pastorino L; Spagnolo F; Dalmasso B; Cabiddu F; Gualco M; Ballestrero A; Bianchi-Scarrà G; Queirolo P; Grillo F; Mastracci L; Ghiorzo P;
Oncotarget; 2017 Jan; 8(5):8069-8082. PubMed ID: 28039443
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
[TBL] [Abstract][Full Text] [Related]
7. Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes.
Jurkowska M; Gos A; Ptaszyński K; Michej W; Tysarowski A; Zub R; Siedlecki JA; Rutkowski P
Int J Clin Exp Pathol; 2015; 8(7):8487-93. PubMed ID: 26339422
[TBL] [Abstract][Full Text] [Related]
8. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
10. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
[TBL] [Abstract][Full Text] [Related]
11. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
[TBL] [Abstract][Full Text] [Related]
12. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
[TBL] [Abstract][Full Text] [Related]
13. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
[TBL] [Abstract][Full Text] [Related]
14. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemistry using clone VE1 is an economic, specific and sensitive method for detecting the presence of BRAFV600E mutations in melanoma].
Etienne M; Oca F; Prunier-Mirebeau D; Croué A; Martin L
Ann Dermatol Venereol; 2018 Mar; 145(3):159-165. PubMed ID: 29221650
[TBL] [Abstract][Full Text] [Related]
16. Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
Colomba E; Hélias-Rodzewicz Z; Von Deimling A; Marin C; Terrones N; Pechaud D; Surel S; Côté JF; Peschaud F; Capper D; Blons H; Zimmermann U; Clerici T; Saiag P; Emile JF
J Mol Diagn; 2013 Jan; 15(1):94-100. PubMed ID: 23159108
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
18. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
